IOmx Therapeutics
Munich
About IOmx Therapeutics
iOmx Therapeutics focuses on the development of first-in-class cancer therapeutics addressing novel immune checkpoint modulators on tumor cells. By systematically screening human tumor cells, the Company has already identified a number of novel targets and analyzed their mode of action. The Company was founded on the successful concept of cancer immune-checkpoint therapy, which works by breaking down the inherent resistance mechanisms of tumors against immune attack. Immune resistance of tumors is often mediated by cell surface molecules that stimulate immune-inhibitory receptors on T cells. Reactivating the host immune response by neutralizing these negative interactions is the idea behind cancer immune-checkpoint therapy.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $120.0M
- Funding stage: Early Stage Venture
- Last round: Series B (Oct 2021)
- Website: iomx.com
- Phone: 49 (0)89 8999 7090 0
Industries & Categories
Biopharma, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/iomx-therapeutics-118616 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.